FDA approves Ofev for the treatment of scleroderma

By NewsDesk¬†¬†@infectiousdiseasenews On Friday, the U.S. Food and Drug Administration approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. Scleroderma is a rare disease that causes … Continue reading FDA approves Ofev for the treatment of scleroderma